HomeCompareRLFTD vs JEPQ

RLFTD vs JEPQ: Dividend Comparison 2026

RLFTD yields 49.02% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RLFTD wins by $329.7K in total portfolio value
10 years
RLFTD
RLFTD
● Live price
49.02%
Share price
$4.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$374.5K
Annual income
$74,708.98
Full RLFTD calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — RLFTD vs JEPQ

📍 RLFTD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLFTDJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLFTD + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLFTD pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLFTD
Annual income on $10K today (after 15% tax)
$4,166.67/yr
After 10yr DRIP, annual income (after tax)
$63,502.63/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, RLFTD beats the other by $61,672.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLFTD + JEPQ for your $10,000?

RLFTD: 50%JEPQ: 50%
100% JEPQ50/50100% RLFTD
Portfolio after 10yr
$209.7K
Annual income
$38,430.78/yr
Blended yield
18.33%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLFTD buys
0
JEPQ buys
0
No recent congressional trades found for RLFTD or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLFTDJEPQ
Forward yield49.02%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$374.5K$44.8K
Annual income after 10y$74,708.98$2,152.59
Total dividends collected$297.4K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: RLFTD vs JEPQ ($10,000, DRIP)

YearRLFTD PortfolioRLFTD Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$15,602$4,901.96$11,930$1,110.39+$3.7KRLFTD
2$23,842$7,147.68$14,133$1,224.34+$9.7KRLFTD
3$35,719$10,208.01$16,632$1,340.46+$19.1KRLFTD
4$52,512$14,292.70$19,454$1,457.97+$33.1KRLFTD
5$75,825$19,637.72$22,626$1,576.08+$53.2KRLFTD
6$107,634$26,501.16$26,175$1,694.09+$81.5KRLFTD
7$150,326$35,157.45$30,133$1,811.32+$120.2KRLFTD
8$206,739$45,889.95$34,531$1,927.17+$172.2KRLFTD
9$280,193$58,982.29$39,403$2,041.08+$240.8KRLFTD
10$374,515$74,708.98$44,787$2,152.59+$329.7KRLFTD

RLFTD vs JEPQ: Complete Analysis 2026

RLFTDStock

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Full RLFTD Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this RLFTD vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLFTD vs SCHDRLFTD vs JEPIRLFTD vs ORLFTD vs KORLFTD vs MAINRLFTD vs XYLDRLFTD vs QYLDRLFTD vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.